Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes

T Yatabe,1,2 S Mochizuki,1 M Takizawa,1 M Chijiwa,1 A Okada,1 T Kimura,1 Y Fujita,1,2 H Matsumoto,2 Y Toyama,2 Y Okada1

ABSTRACT

Background: Intra-articular injection of hyaluronan (HA) has been suggested to have a disease-modifying effect in osteoarthritis, but little is known about the possible mechanisms.

Objective: To investigate the effects of HA species of different molecular mass, including 800 kDa (HA800) and 2700 kDa (HA2700), on the expression of aggrecanases (ie, ADAMTS species), which play a key role in aggrecan degradation.

Methods: The effects of HA species on the expression of ADAMTS1, 4, 5, 8, 9 and 15 in interleukin 1α (IL1α)-stimulated osteoarthritic chondrocytes were studied by reverse transcription PCR and real-time PCR. Expression of ADAMTS4 protein and aggrecanase activity and signal transduction pathways of IL1, CD44 and intracellular adhesion molecule 1 (ICAM1) were examined by immunoblotting.

Results: IL1α treatment of chondrocytes induced ADAMTS4, and HA800 and HA2700 significantly decreased IL1α-induced expression of ADAMTS4 mRNA and protein. IL1α-stimulated aggrecanase activity in osteoarthritic chondrocytes was reduced by treatment with HA2700 or transfection of small interfering RNA for ADAMTS4. A similar result was obtained when HA2700 was added to explant cultures of osteoarthritic cartilage. HA2700 neither directly inhibited nor bound to ADAMTS4. Downregulation of ADAMTS4 expression by HA2700 was attenuated by treatment of IL1α-treated chondrocytes with antibodies to CD44 and/or ICAM1. The increased phosphorylation of IL1 receptor-associated kinase-1 and extracellular signal-regulated protein kinase1/2 induced by the IL1α treatment was downregulated by enhanced IRAK-M expression after HA2700 treatment.

Conclusion: These data suggest that HA2700 suppresses aggrecan degradation by downregulating IL1α-induced ADAMTS4 expression through the CD44 and ICAM1 signalling pathways in osteoarthritic chondrocytes.

Aggrecan degradation and subsequent digestion of collagen fibrils make up the central pathway for the destruction of cartilage in osteoarthritis (OA). Collagen degradation is carried out principally by collagen-degrading matrix metalloproteinases (MMPs) such as MMP1, MMP8 and MMP13.1–3 On the other hand, aggrecan-degrading metalloproteinases, called aggrecanases, are considered to play a key role in aggrecan degradation.4–6 Aggrecanases belong to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) gene family, and ADAMTS1, 4, 5, 8, 9 and 15 are known to have aggrecanase activity.4–6

Studies using ADAMTS4 and ADAMTS5 knockout mice have indicated that ADAMTS5, but not ADAMTS4, has an essential role in aggrecan degradation in mice.7,8 However, because there is little information about the biochemical character, expression patterns or gene promoter structures of mouse ADAMTS4 and ADAMTS5, the data from knockout mice must be interpreted with care and should not be extrapolated to the human disease.9,10 In human chondrocytes, ADAMTS4 is inducible by treatment with cytokines such as interleukin 1 (IL1), but the expression of ADAMTS5 is constitutive.11–13 Our recent study also showed that, of the aggrecanase-type ADAMTS species, ADAMTS4 is selectively overexpressed in human osteoarthritic cartilage, with a direct correlation with the degree of cartilage destruction, whereas ADAMTS5 is constitutively expressed in both normal and osteoarthritic cartilage.14 These results suggest that ADAMTS4 is a major aggrecanase in human osteoarthritic cartilage.

Hyaluronan (HA) is widely used to treat OA of the knee by intra-articular injection. The effects are reported to depend on the molecular mass of the HA species,14,15 which can be classified as very low (50 kDa), low (500 kDa), medium (800 kDa) or high (2000–3000 kDa) according to a consensus reached at the 7th International Conference on Hyaluronan (South Carolina, 2007). Symptom-modifying effects of medium and high molecular mass HA, including relief of joint pain, have been demonstrated,14,15 but some experimental and clinical studies have provided evidence that these HA species also have potentially disease-modifying effects.14,16–18 HA of 2700 kDa (HA2700) has been shown to be a potent inhibitor of proteoglycan release from the cell matrix of rabbit chondrocyte cultures.19 Previous studies20–21 have also shown that HA of 800 kDa (HA800) inhibits IL1-stimulated production of MMP1, MMP3 and MMP13 through interaction with CD44, a major receptor for HA on chondrocytes and synoviocytes, although the authors did not search for effects on the signalling pathway of CD44. On the other hand, intra-articular injection of HA800 in a rabbit OA model has been reported to suppress osteoarthritic changes without inhibiting expression of MMP3.22 These data suggest that the chondroprotective effect of medium and high molecular mass HA may be due to inhibition of aggreganases as well as MMPs. At this juncture, however, little or no information is available on the effects of HA on aggrecanases in human osteoarthritic chondrocytes or cartilage.
In this study, we examined the effects of HA species on the expression of ADAMTS1, 4, 5, 8, 9 and 15 in osteoarthritic chondrocytes stimulated with IL1, one of the most powerful stimulators of proteinase production.23 As HA2700 inhibited IL1-induced expression of ADAMTS4, we also studied the signalling pathways through interaction between HA2700 and HA receptors.

METHODS
Chondrocyte cultures
Non-osteophytic articular cartilage was obtained at arthroplasty from knee or hip joints of patients with OA diagnosed according to the criteria of the American College of Rheumatology.24 Chondrocytes were isolated from the cartilage,25 and the cultured cells were confirmed to be of chondrocyte phenotype by the positive immunostaining of aggrecan and type II collagen.26 Chondrocytes were starved of serum in Dulbecco’s modified Eagle’s medium/Ham’s F-12 (DMEM/F-12) containing 0.2% lactalbumin hydrolysate, and then treated with IL1a in the presence or absence of HA species of different molecular mass, including 1.2 kDa (HAoligo), 300 kDa (HA300), 800 kDa (HA800) and 2700 kDa (HA2700), all of which were gifts from Chugai Pharmaceutical Co (Tokyo, Japan). The molecular mass of HA2700, which is known as Suvenyl (Chugai Pharmaceutical Co) and used to treat knee OA, was determined by the multi-angle laser light scattering method.27 We used 1 ng/ml IL1a and 2.5 mg/ml HA species (except for HAoligo), as these concentrations of IL1a and HA showed a definite stimulatory effect on ADAMTS4 expression and a maximal inhibitory effect on IL1a-induced ADAMTS4 expression, respectively (data not shown). HAoligo was used at a concentration of 250 μg/ml according to data from a previous study.28 The non-cytotoxic effect of these HA species on cultured chondrocytes was confirmed using an MTT assay kit (Nacalai Tesque Corp, Kyoto, Japan).29 Informed consent was obtained from patients according to the hospital ethics guidelines for the experimental use of the samples.

Reverse transcription (RT)-PCR
Total RNA extracted from cultured chondrocytes was reverse-transcribed to cDNA, and PCR amplification by Ex Taq DNA polymerase (Takara Bio, Otsu, Japan) was performed using primers specific for ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8, ADAMTS9, MMP1, MMP2, MMP3, MMP13, membrane type (MT)1-MMP, MT4-MMP, tissue inhibitor of metalloproteinases 3 (TIMP3) and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as described previously.10 30 31 Positive control experiments were carried out as described elsewhere.10

Real-time quantitative PCR
The relative mRNA expression ratios of ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8, ADAMTS9, MMP1, MMP2, MMP3, MMP13, membrane type (MT)1-MMP, MT4-MMP, tissue inhibitor of metalloproteinases 3 (TIMP3) and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as described previously.10 Sequences of the primers and TaqMan probe are provided as supplementary material 1.

Immunoblotting of ADAMTS4
Chondrocytes were cultured in serum-free DMEM/F-12 in the presence or absence of IL1a. Cell lysates and conditioned medium were subjected to sodium dodecyl sulphate/polyacrylamide gel electrophoresis (SDS/PAGE) under reduction,33 and immunoblotted with antibodies to ADAMTS4 (247-3F6 and 250-4F7) or GAPDH (Abcam, Cambridge, UK) as described previously.10 The specificity of monoclonal antibodies to the spacer domain (247-3F6) or a portion of the disintegrin and thrombospondin domains (250-4F7) of human ADAMTS4 has been demonstrated.10 Both antibodies were able to immunoprecipitate ADAMTS4 (supplementary material 2).

Figure 1   Effects of hyaluron (HA) species on mRNA expression of ADAMTS species in interleukin (IL)1α-stimulated osteoarthritic chondrocytes. (A) Reverse transcription-PCR analysis of the expression of ADAMTS species and tissue inhibitor metalloproteinase 3 (TIMP3). Total RNA was isolated from the chondrocytes which were treated for 24 h without (Cont) or with IL1α (1 ng/ml) and HA (250 μg/ml for HAoligo and 2.5 mg/ml for other HA species), and reverse-transcribed into cDNA followed by PCR. The experiments were carried out in triplicate, and representative data are shown. Positive controls (PC) are rheumatoid synovial fibroblasts for ADAMTS1, ADAMTS5 and TIMP3, U-251 human glioblastoma cells for ADAMTS4, ADAMTS9 and ADAMTS15, and CaR-1 rectal carcinoma cells for ADAMTS8.10 (B) Real-time PCR analysis of the mRNA expression of ADAMTS4. Relative expression levels of ADAMTS4 in osteoarthritic chondrocytes treated without (Cont) or with IL1α and HA species were normalised to an endogenous control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Bars are mean (SD) (n = 5). *p<0.05; **p<0.01; ***p<0.001.
Detection of aggrecanase activity in osteoarthritic chondrocytes and articular cartilage

Chondrocytes were cultured for 5 days in serum-free DMEM/F-12 containing 100 mg/ml aggrecan isolated from porcine nasal cartilage in the presence or absence of IL1α. Aggrecanase activity was detected by immunoblotting aggrecan fragments in the medium using anti-aggrecan neoepitope (NITEGE373)-specific antibody (2 μg/ml). The effects of HA2700, KB-R7785 (a synthetic ADAM inhibitor) and TIMP3 (a natural inhibitor of aggrecanases) on the aggrecanase activity of the IL1α-stimulated chondrocytes were evaluated by immunoblotting. Similarly, the effects of HA2700 and KB-R7785 on the activity in osteoarthritic cartilage were examined by immunoblotting after culture of cartilage tissue slices in serum-free DMEM/F-12 containing 0.2% lactalbumin hydrolysate and IL1α. After the reactions, the samples were freeze-milled under liquid nitrogen and pulverised. The concentration of glycosaminoglycan in proteoglycans extracted from the cartilage powder was determined by colorimetric assay. The inhibitory activity of KB-R7785 on ADAMTS4 was confirmed in an assay of aggrecan digestion using recombinant ADAMTS4 (data not shown).

Transfection of small interfering RNA (siRNA) for ADAMTS4

The siRNA for ADAMTS4 (CCATCAATGGAGATCCGGAGT) (Ambion Inc, Austin, Texas, USA) were custom synthesised and transfected to IL1α-stimulated osteoarthritic chondrocytes and cartilage (see supplementary material 3 for detailed conditions). Expression of ADAMTS4 after siRNA transfection was monitored by RT-PCR and immunoblotting, and aggrecanase activity was detected by immunoblotting as described above.

Blocking of HA2700 binding to chondrocytes with antibodies to HA receptor, and analysis of cell signalling

Chondrocytes were incubated with neutralising CD44 antibody (BD Biosciences, San Diego, California, USA), ICAM1 antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, California, USA) or non-immune IgG (BD Biosciences), and then cultured in serum-free DMEM/F-12 with or without HA2700 in the presence or absence of IL1α. ADAMTS4 expression was monitored by RT-PCR, real-time PCR and immunoblotting. For the study of cell signalling, chondrocytes were cultured under similar conditions, and the cell lysates were subjected to SDS/PAGE for immunoblotting analyses using rabbit polyclonal antibodies to IRAK1, phospho-IRAK1, IRAK-M, extracellular signal-regulated protein kinase1/2 (ERK1/2) or phospho-ERK1/2 (Cell Signalling Technology Co, Beverly, Massachusetts, USA). The effect of mitogen-activated protein kinase kinase (MEK) inhibitor on ERK1/2 phosphorylation and expression of ADAMTS4 was also examined by treating chondrocytes with PD98059 (Calbiochem, San Diego, California, USA).

Figure 2 Effects of hyaluron (HA) species on ADAMTS4 protein expression in osteoarthritic chondrocytes.

Chondrocytes were cultured in the absence (Cont) or presence of interleukin (IL)1α (1 ng/ml) and HA (250 μg/ml for HA oligo and 2.5 mg/ml for other HA species) for 72 h, and then ADAMTS4 protein expression in cell lysates (A) and culture medium (B) was analysed by immunoblotting with ADAMTS4 antibody (0.5 μg/ml; 250-4F7). Arrows indicate ADAMTS4 of molecular mass 73 kDa and 58 kDa. The protein bands were densitometrically analysed and compared. Note that treatment with HA800 and HA2700 significantly decreased the level of expression of ADAMTS4 protein in both cell lysates and culture media. Bars are mean (SD) (n = 5), *p<0.05; **p<0.01; ***p<0.001. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Effects of HA on mRNA expression of ADAMTS species, MMPs and TIMP3

RT-PCR analysis showed that IL1α treatment of osteoarthritic chondrocytes induces expression of ADAMTS4 and stimulates expression of TIMP3 (fig 1A). ADAMTS1, ADAMTS5 and ADAMTS9 were constitutively expressed, and ADAMTS15 expression decreased under stimulation with IL1α. Negligible expression of ADAMTS8 was observed even under IL1α stimulation. When IL1α-stimulated chondrocytes were treated with HA species, the expression of ADAMTS4, ADAMTS5 and ADAMTS9 appeared to decrease in a manner directly related to the molecular mass of the HA used (fig 1A). However, no definite decrease in the expression of ADAMTS1, ADAMTS15 and TIMP3 was obtained by the treatment. Similar inhibitory effects of the HA species on the IL1α-stimulated expression of MMPs, MMP13, MT1-MMP and MT4-MMP were observed (supplementary material 5).

Real-time PCR showed that the expression level of ADAMTS4 was enhanced 17-fold by IL1α (p < 0.001), and the IL1α-induced expression was decreased to 70% and 50% by treatment with HA800 (p < 0.05) and HA2700 (p < 0.01), respectively, but not with HAoligo or HA300 (fig 1B). No changes in ADAMTS1 expression level were observed in chondrocytes treated or not with IL1α and/or HA species, and negligible expression of ADAMTS8 was detected (supplementary material 6). Although the concentrations of ADAMTS5 and ADAMTS9 in the control and IL1α treated samples did not differ, they were significantly decreased by treatment with HA2700 (p < 0.05) (supplementary material 6). The level of ADAMTS15 expression was significantly decreased after treatment with IL1α (p < 0.01), but no effects of HA species on the expression were seen (supplementary material 6).

Effects of HA on protein expression of ADAMTS4

On immunoblotting, cell lysates from IL1α-stimulated chondrocytes but not control untreated chondrocytes showed a band of 75 kDa, whereas a major band of 58 kDa was detected in culture medium from IL1α-treated chondrocytes but not control chondrocytes (fig 2A,B). These two ADAMTS4 species were recognised by both antibodies (247-3F6 and 250-4F7). When the IL1α-stimulated chondrocytes were treated with HA species, the bands of ADAMTS4, ADAMTS5 and ADAMTS9 appeared to decrease in a manner directly related to the molecular mass of the HA used (fig 1A). However, no definite decrease in the expression of ADAMTS1, ADAMTS15 and TIMP3 was obtained by the treatment. Similar inhibitory effects of the HA species on the IL1α-stimulated expression of MMPs, MMP13, MT1-MMP and MT4-MMP were observed (supplementary material 5).

Real-time PCR showed that the expression level of ADAMTS4 was enhanced 17-fold by IL1α (p < 0.001), and the IL1α-induced expression was decreased to 70% and 50% by treatment with HA800 (p < 0.05) and HA2700 (p < 0.01), respectively, but not with HAoligo or HA300 (fig 1B). No changes in ADAMTS1 expression level were observed in chondrocytes treated or not with IL1α and/or HA species, and negligible expression of ADAMTS8 was detected (supplementary material 6). Although the concentrations of ADAMTS5 and ADAMTS9 in the control and IL1α-treated samples did not differ, they were significantly decreased by treatment with HA2700 (p < 0.05) (supplementary material 6). The level of ADAMTS15 expression was significantly decreased after treatment with IL1α (p < 0.01), but no effects of HA species on the expression were seen (supplementary material 6).

Inhibition of aggrecanase activity with HA2700

Aggrecanase activity was monitored by immunoblotting using an aggrecan neoeptope-specific antibody. As shown in fig 5A, non-stimulated chondrocytes showed an immunoreactive band of ~70 kDa, and the intensity of the band increased after
treatment with IL1α. Importantly, the band intensity in the IL1α-treated chondrocytes was reduced to basal level by treatment with HA2700, and almost disappeared on treatment with KB-R7785 or TIMP3, whereas no such inhibition was observed with HAoligo (fig 3A). Transfection of IL1α-stimulated chondrocytes with ADAMTS4 siRNA abrogated the mRNA and protein expression of ADAMTS4, whereas no changes in expression were obtained with non-silencing siRNA (fig 3B). Accordingly, aggrecanase activity observed after IL1α treatment decreased to basal level by transfection of ADAMTS4 siRNA but not non-silencing siRNA (fig 3B). Similar effects of HA2700 and ADAMTS4 siRNA on aggrecanase activity were obtained in osteoarthritic cartilage tissue slices; IL1α-induced aggrecanase activity was reduced to basal level by treatment with HA2700, KB-R7785 or siRNA (fig 3C).

When the direct action of HA2700 on ADAMTS4 was examined, neither inhibition of ADAMTS4 activity nor binding of ADAMTS4 species to HA2700 was observed (supplementary material 7). Involvement of CD44 and ICAM1 in inhibitory effect of HA2700 on ADAMTS4 expression

The inhibitory effect of HA2700 on ADAMTS4 expression was partially attenuated by treatment with antibody to CD44 (p<0.05) or ICAM1, and almost completely with both antibodies (p<0.01) (fig 4A), although the antibody showed no effects on IL1α-induced ADAMTS4 expression (data not shown). The effect of the antibody on HA2700-induced inhibition of ADAMTS4 expression was confirmed by immunoblotting of cell lysates (fig 4B).

Figure 4  Analysis of the involvement of the CD44 and intracellular adhesion molecule 1 (ICAM1) signalling pathways in the HA2700 inhibitory effect on ADAMTS4 expression. (A,B) Effect of CD44 antibody (αCD44) and ICAM1 antibody (αICAM1) on the inhibition of ADAMTS4 expression with HA2700. Osteoarthritic chondrocytes were allowed to react for 1 h with buffer alone, non-immune IgG (20 μg/ml; data not shown), αCD44 (20 μg/ml), αICAM1 (20 μg/ml) or αCD44 (20 μg/ml) + αICAM1 (20 μg/ml), treated with 2.5 mg/ml HA2700 for 24 h, and then cultured for 24 h for the real-time PCR analysis of ADAMTS4 gene expression (A) and for 48 h for immunoblotting analysis of ADAMTS4 protein (B) after the addition of IL1α (1 ng/ml) to the culture medium. Bars are mean (SD) (n = 3). *p<0.05; **p<0.01. (C) Analysis of signalling pathways of IL1 and CD44 under treatment with HA2700. Expression of IL1 receptor-associated kinase-1 (IRAK1), extracellular signal-regulated protein kinase1/2 (ERK1/2) and IRAK-M and phosphorylation of IRAK1 and ERK1/2 were examined by immunoblotting of osteoarthritic chondrocytes. The cells were cultured for 24 h in the absence (Cont and None) or presence (2.5 mg/ml) of HA2700, and then stimulated for 30 min without or with IL1α (1 ng/ml), followed by immunoblotting for p-IRAK1, IRAK1, p-ERK1/2, ERK1/2 and IRAK-M. The effect of αCD44 on HA2700-induced signalling was examined as described above. (D) Involvement of mitogen-activated protein kinase kinase (MEK) in ADAMTS4 expression and phosphorylation of ERK1/2. Chondrocytes were treated for 30 min without or with PD98059 (50 μM). Then, the cells were cultured in the absence or presence of IL1α (1 ng/ml) for 48 h for immunoblotting of ADAMTS4 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or for 30 min for immunoblotting of p-ERK1/2 and ERK1/2. All experiments were performed in triplicate.
**Figure 5** Hypothesis of the signalling pathways for HA2700 inhibition of ADAMTS4 expression in IL1α-stimulated osteoarthritic chondrocytes. The IL1α signal via IL1 receptor is transduced by IRAK1 and may enhance ADAMTS4 expression through the MAP kinase and NF-κB pathways. Binding of HA2700 to CD44 induces IRAK-M, which inhibits IRAK1 and subsequently suppresses phosphorylation of ERK1/2 and finally ADAMTS4 expression. HA2700 also binds to ICAM1 and this binding may inhibit NF-κB and subsequently suppress ADAMTS4 expression.

To analyse the signalling pathways, we examined phosphorylation of IRAK1 and ERK1/2. The phosphorylation of both molecules was enhanced by IL1α treatment, and the IL1α-induced phosphorylation was downregulated by treatment with HA2700 (fig 4C). HA2700 treatment of IL1α-treated or untreated chondrocytes induced the expression of IRAK-M, a negative regulator of IRAK1, via CD44. Inhibition of IL1α-induced phosphorylation of IRAK1 and ERK1/2 was attenuated by treatment of the cells with CD44 antibody, and induction of IRAK-M by HA2700 was abolished by incubation with the antibody (fig 4C). In addition, phosphorylation of ERK1/2 and expression of ADAMTS4 were abrogated by treatment with PD98059, a MEK inhibitor (fig 4D). These results suggest that IRAK-M induced by HA2700 binding to CD44 has a key role in downregulation of the IL1α-stimulated signalling pathway, and MEK is involved in the ERK1/2 phosphorylation.

**DISCUSSION**

Conflicting data have been reported on the expression of aggrecan-degrading ADAMTS species: some studies have reported that ADAMTS4 is upregulated by IL1, tumour necrosis factor α, oncostatin M and transforming growth factor β, but others have shown that IL1 treatment does not affect ADAMTS4 expression. Our systematic analyses of ADAMTS4 expression in human osteoarthritic chondrocytes under monolayer culture have provided the first evidence that IL1α selectively induces ADAMTS4 expression, whereas ADAMTS5, ADAMTS8 and ADAMTS9 are constitutively expressed, and ADAMTS8 is negligibly expressed without being affected by IL1α. Treatment of chondrocytes with tumour necrosis factor α and oncostatin M has been reported to downregulate ADAMTS15, but our study showed that IL1α also functions as a suppressor of ADAMTS15 expression.

Although previous studies have shown that HA800 suppresses the production of MMP1, MMP5 and MMP13 by osteoarthritic and normal cartilage explants, our study is the first to show that 2.5 mg/ml of HA2700 and HA800, which is within the physiological concentration range in synovial fluids (2–4 mg/ml), inhibits the mRNA and protein expression of ADAMTS4 in osteoarthritic chondrocytes. The effect of HA is known to depend on its molecular mass. Indeed, our study shows significant inhibition of ADAMTS4 expression with only HA2700 and HA800, but not with HA500 or HAoligo. When the effects were compared, HA2700 was considered to be the more efficient suppressor of expression of aggrecan-degrading ADAMTS species, as inhibition of ADAMTS4 expression appeared to be greater with HA2700 than with HA800, and HA2700, but not HA800, significantly inhibited the expression of ADAMTS5 and ADAMTS9.

This study shows that IL1α-induced aggrecanase activity in cultured chondrocytes and osteoarthritic cartilage explants is suppressed by treatment with HA2700. Although TIMP3 is an efficient inhibitor of ADAMTS4, IL1α-stimulated TIMP3 expression appeared to be unchanged by HA2700 treatment. HA2700 did not directly inhibit ADAMTS4 activity or bind to ADAMTS4. siRNA for ADAMTS4 suppressed IL1α-induced aggrecanase activity in cultured chondrocytes and cartilage tissue. Therefore, these data suggest that HA2700 inhibition of aggrecanase activity may be due principally to reduced expression and production of ADAMTS4. On the other hand, our finding that treatment with synthetic inhibitor and TIMP3 appeared to reduce aggrecanase activity to below that of untreated osteoarthritic chondrocytes suggests that such strong inhibition may be due to simultaneous suppression of aggrecanase(s) such as constitutively expressed ADAMTS8.

Previous studies have shown the involvement of CD44 in the HA effects. No previous studies have clarified the intracellular signalling pathways. As binding of HA to CD44 on activated monocytes is known to modulate IL1-induced signalling by inducing the expression of IRAK-M, which suppresses IRAK1, we examined the expression of these signalling molecules. We found that HA2700 treatment reduces IL1α-stimulated phosphorylation of IRAK1 and ERK1/2 through induction of IRAK-M. These data suggest that...
HA2700, at least in part, inhibits the IL1 receptor signalling pathway of IRAK1 and ERK1/2 by the action of IRAK-M (fig 5). However, as the recovery with CD44 antibody was partial, other pathways of HA receptors, including ICAM1 and Toll-like receptor (TRL2) and 4, appear to be involved. In fact, the finding that treatment with both CD44 antibody and ICAM1 antibody attenuated the inhibition suggests the involvement of both CD44 and ICAM1 pathways (fig 5). It is, however, unlikely that TRL2 and TRL4 act as receptors for HA in osteoarthritic cartilages, as neither the expression of these molecules nor any effect of their antibodies on the recovery was observed in the cartilages (data not shown).

Intra-articular administration of HA2700 and HA800 is widely used as a symptom-modifying treatment for knee OA; and growing experimental and clinical evidence suggests that HA2700 and HA800 may also modify the structure of diseased joints and slow the rate of OA disease progression. The potential disease-modifying effect seems to be explained by positive regulation of joint repair through stimulation of cartilage growth metabolism and synthesis of cartilage matrix and suppression of inflammatory processes. However, HA800 has been reported to inhibit the production of MMP1, MMP5, and MMP18 in normal and osteoarthritic cartilage treated with IL1β, and the present study shows suppression of ADAMTS4 expression by HA2700 and HA800. Thus, we hypothesise that HA2700 and HA800 protect the cartilage from damage in OA by inhibiting the expression of chondrodegradative metalloproteinases, i.e., ADAMTS4 and MMPs. Clinical trials of the disease-modifying effect of HA2700 on OA are necessary.

Acknowledgements: We thank Dr Edward D Harris, Jr (Stanford University School of Medicine) for reviewing the manuscript. We are also grateful to Ms Mayumi Kishi for her technical assistance.

Funding: Grant-in-Aid from the Ministry of Education, Science and Culture of Japan (18060038 and 19109004) to YO.

Competing interests: None.

Ethics approval: Obtained.

Patient consent: Obtained.

REFERENCES


